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The mammalian heart must maintain its structural and 
functional integrity for decades, yet the response to 
damage in this vital organ is remarkably inadequate and 
often results in heart failure. Moreover, patients with 
chronic heart failure show profound metabolic changes, 
leading to peripheral abnormalities in addition to an 
initial cardiac impairment. Several evidences have 
suggested a relationship between the IGF-1 system and 
cardiovascular disease. Many cardiovascular risk 
factors, such as sedentary lifestyle, diabetes, smoking, 
oxidized low-density lipoprotein, obesity, psychological 
distress and reduced coronary flow reserve, have been 
associated with reduced IGF-1 levels [1]. Conversely, 
human studies indicate that increased levels of IGF-1 
are characterized by a decreased incidence of heart 
failure and mortality in elderly individuals [2]. 
Nevertheless, the fact that IGF-1 can act either as a 
circulating hormone or as a local growth factor has 
confounded previous analyses of animal models in 
which transgenic IGF synthesized in extra-hepatic 
tissues was released into the circulation. Locally acting 
mIGF-1 isoform improves muscle regeneration and 
counters muscle wasting associated with diseases, 
including sarcopenia, muscular dystrophy and ALS [3]. 
By contrast, circulating IGF-1 isoforms have been 
implicated in the restriction of lifespan and have 
contrasting effects on the heart when expressed as 
transgenes, variously promoting cell survival, or 
inducing prolonged hypertrophy with pathological 
consequences [4]. Another important mediator of cell 
homeostasis with cardio-protective effects is SIRT1, the 
largest and best characterized member of the Sirtuin 
family. Is there any functional interplay between IGF-1 
signaling and SIRT1 expression and activity? The study 
of Bolasco et al [5]  addresses this point and offers 
some fascinating insights into the molecular mechanism 
by which the cardiac mIGF-1/SIRT1 pathway in mice, 
has a global impact on the regulation of the immune 
system, the arterial blood pressure and also the 
behavioral response to fear. In their previous work, the 
authors demonstrated that heart-specific transgenic 
mIGF-1 mice are able to recover heart function after 
damage by the modulation of inflammatory response, 
enhancement of antioxidative cell defenses, and de novo 
vascularization. This impact of IGF-1 on the mouse 
heart may be operative through the activation of  SIRT1,                          
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since in the absence of SIRT1expression in cardiac 
muscle, mIGF-1 activity could not protect the heart 
from oxidative stress and lethality [6]. 
To explain why the cardiomyocytes of mIGF-1 mice 
respond better to specific types of stress (e.g. ischemia, 
angiotensin II, cardiotoxin injection, paraquat injection) 
Bolasco et al performed transcriptomic analyses on the 
hearts of mIGF‐1 transgenic versus wild type mice, in 
absence of any injury. Interestingly, the variations in the 
mIGF-1/SIRT1 genomic and transcriptomic effects 
were related to genes implicated in the immune 
response, the blood pressure control, inflammation and 
behavior. This suggests that: 
1) IGF-1/SIRT1 pathway regulates functions 
beyond cardiomyocyte specific homeostatic and 
protective mechanisms, 
2) the cardioprotective mIGF-1/SIRT1 pathway 
might elicit a global impact on body functions. 
Of interest was the observation that in absence of 
damage, local mIGF-1 cardiac expression induces an 
up-regulation of relevant genes associated with the 
regulation of immune function. How this “supra-basal” 
activation of the immune system is compatible with a 
better cardiac function? 
 
The impact of cardioprotective mIGF-1 pathway on 
immune and cardiovascular stress is coherent with the 
concept of hormesis, which is an adaptive response of 
cells and organisms to a moderate stress. Recent 
findings have elucidated the cellular signaling pathways 
and molecular mechanisms that mediate hormetic 
responses which typically involve enzymes such as 
kinases and deacetylases, and transcription factors [7]. 
In this context, SIRT1, an important member of the 
Sirtuin family of nicotinamide adenine dinucleotide 
(NAD+)-dependent protein deacetylases, might 
participate in the hormetic response of mIGF-1 cardiac 
muscle. The activation of the immune system, by 
cardiac mIGF-1 expression, would also suggest that 
mIGF-1 guarantees a constant turnover of cardiac stem 
cells and cardiomyocytes. Of note, different studies of 
the group of Rosenthal, Musarò and Vinciguerra clearly 
indicated that mIGF-1 exerts its anabolic role, in both 
cardiac and skeletal muscle, acting on stem cell 
compartments. Another important and surprisingly 
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finding of the study by Bolasco et al. was the 
observation that mIGF-1 transgenic mice were mildly 
hypertensive and this effect could be rescued by 
cardiomyocyte specific depletion of SIRT1. Although 
the authors did not define a causal link between high 
blood pressure and cardiac mIGF-1/SIRT1 pathway, it 
is possible that the activation of immune system plays a 
critical role in the modulation of blood pressure. Indeed, 
inflammation is recognized as an important factor in the 
pathophysiology of hypertension [8]. Although the 
hypertension is considered a pathologic events which 
also favors a decline in memory, a study in centenarians 
showed conversely that high blood pressure is 
associated to improved cognitive functions [9]. 
Interestingly, Bolasco and collaborators demonstrated 
that mice harboring mIGF-1 transgene in the heart had a 
better memory of the aversive stimulus, for both cue 
and context fear response, in that they spent a 
significant augmented time in a frozen position 
compared to wild type littermates. This was strictly 
dependent on the presence of SIRT1.  
 
Thus, a primed immune system can constitute an 
hormetic advantage for responding to a potential cardiac 
tissue damage. In this context, further studies should 
better address the causes of hypertension, taking into 
consideration epigenetic phenomena and environmental 
factors. This would help to better define whether 
essential hypertension could be replaced by other terms 
with precise pathophysiological characteristics. 
Together, these observations support hypothesis that the 
mIGF-1/SIRT1 pathway maintains the “youth heart” 
and renders the cardiac muscle more responsive and 
resistant to different pathologic stimuli. 
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